Search | Clinical Trials Finder

Conditions: Tinnitus
Interventions: DMSO-based otic solution with betahistine, dexamethasone, and lidocaine, DMSO-based transdermal cream with levocarnitine and N-acetylcysteine; Drug
Lead sponsor: Leading Edge Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Ithaca, New York

Conditions: COVID-19
Interventions: STX-S; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Rochester, New York • Seattle, Washington

Conditions: Health Equity, COVID-19
Interventions: First Come, First Served, Random, Disadvantaged Priority & Random; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 2,019 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Multiple Sclerosis, COVID-19
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 154 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: SARS-CoV-2
Interventions: mRNA-1273, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30,415 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 100
States / cities: Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 79 more

Conditions: Coronavirus Disease (COVID-19)
Interventions: V590, Placebo; Biological · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 232 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 7
States / cities: Tempe, Arizona • Miami, Florida • South Miami, Florida + 4 more

Conditions: COVID-19 Immunization, Influenza Immunization
Interventions: RIV (recombinant influenza vaccine), rC19 (dose 1), RIV + rC19 (dose 1), RIV + rC19 (dose 2), RIV + rC19 (dose 3), RIV + rC19 (dose 4), Placebo (0.9% NaCl); Biological · Other
Lead sponsor: Sanofi; Industry
Eligibility: 50 Years and older
Enrollment: 980 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 12
States / cities: Phoenix, Arizona • Cerritos, California • Vista, California + 9 more

Conditions: SARS-CoV2, COVID-19
Interventions: VXA-CoV2-3.1, COMIRNATY®, VXA-CoV2-3.3; Biological
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years and older
Enrollment: 5,485 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 145
States / cities: Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 126 more

Conditions: Influenza,Human, COVID-19
Interventions: Investigational Influenza Vaccine, COVID-19 Vaccine, Investigational Influenza/COVID-19 Vaccine, Licensed Influenza Vaccine 1, Licensed Influenza Vaccine 2, Placebo; Biological · Combination Product · Other
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 1,353 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 22
States / cities: Lake Forest, California • San Diego, California • Walnut Creek, California + 17 more

Conditions: COVID-19
Interventions: Not listed
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: COVID-19
Interventions: ChAdV68-S, ChAdV68-S-TCE, SAM-LNP-S, SAM-LNP-S-TCE, Sodium Chloride, 0.9%; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Decatur, Georgia • St Louis, Missouri • Houston, Texas + 1 more

Conditions: COVID-19 Immunization, Influenza Immunization
Interventions: IIV-HD, rC19 (dose 1), IIV-HD + rC19 (dose 1), IIV-HD + rC19 (dose 2), IIV-HD + rC19 (dose 3), IIV-HD + rC19 (dose 4), Placebo (0.9% NaCl); Biological · Other
Lead sponsor: Sanofi; Industry
Eligibility: 50 Years and older
Enrollment: 980 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 12
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 9 more

Conditions: Healthy Volunteer
Interventions: Flucelvax, Fluvirin, Fluzone High Dose; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Herpes Zoster, Allergy and Immunology, Corona Virus Infection
Interventions: SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted), Normal Saline; Biological · Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 65 Years to 100 Years
Enrollment: 217 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: COVID-19, SARS-COV-2 Infection
Interventions: BNT162b2 (2025/2026 recommended SARS-CoV-2 strain); Biological
Lead sponsor: BioNTech SE; Industry
Eligibility: 12 Years and older
Enrollment: 774 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 19
States / cities: Walnut Creek, California • Milford, Connecticut • Washington D.C., District of Columbia + 13 more

Conditions: COVID-19 Vaccines, Telemedicine, Vaccine Hesitancy, Pediatric ALL
Interventions: COVID-19 Vaccine Uptake App, General Health App; Behavioral · Other
Lead sponsor: IDeA States Pediatric Clinical Trials Network; Network
Eligibility: 18 Years and older
Enrollment: 1,934 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 15
States / cities: Little Rock, Arkansas • Wilmington, Delaware • Honolulu, Hawaii + 12 more

Conditions: Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Interventions: NVX-CoV2705 Vaccine; Biological
Lead sponsor: Novavax; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Phoenix, Arizona • Austin, Texas

Conditions: COVID-19
Interventions: Bivalent COVID-19 Booster; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 13 Years to 55 Years · Female only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Vaccine Preventable Disease
Interventions: Educational, culturally appropriate COVID-19 messages; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 101 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: COVID-19 Respiratory Infection, SARS CoV 2 Infection, COVID-19 Vaccine
Interventions: CoV-RBD-scNP-001 and 3M-052-AF; Biological
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: SARS-CoV-2
Interventions: CORVax, IL-12 plasmid, Cliniporator; Drug · Device
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Covid19, SARS-CoV2 Infection
Interventions: mRNA-1273; Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Covid19
Interventions: Opt-In (Call-Back), Opt-in (In-Bound), Standard Message, Clinician Endorsement, Scarcity, Opt-Out Framing, Phone Call; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 16 Years and older
Enrollment: 19,554 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Covid19, SARS (Severe Acute Respiratory Syndrome), SARS-CoV Infection, SARS-CoV-2
Interventions: Biological: oral polio vaccine, Comparable Placebo, NA-831, Comparable Placebo of drug, Combination of oral polio vaccine and NA-831, Comparable Placebo of Oral Polio Vaccine and Placebo of drug; Biological · Drug · Combination Product
Lead sponsor: Biomed Industries, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3,600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 8
States / cities: Los Angeles, California • Orange, California • Palo Alto, California + 4 more

Search by objective public record fields.

DMSO Dual-Route Therapy for Refractory Tinnitus in Long-COVID and Post-COVID-19 Vaccine Injury

Safety, Reactogenicity, and Immunogenicity Trial of STX-S SARS-CoV-2 Vaccine in Adults

Public Support for COVID-19 Test Allocation

COVID-19 Vaccine Biomarker Study in Multiple Sclerosis

A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19

Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001)

Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older

A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection

A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People

A Clinical Observational Study of SARS-CoV-2 Specific CD8 T-Cell Responses to COVID-19 Vaccines in Humans

Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults

Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older

Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine

Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents

A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years

Improving Pediatric COVID-19 Vaccine Uptake Using an mHealth Tool

A Strain Change Study for SARS-CoV-2 rS Vaccines

COVID Booster in Pregnancy and Lactation

Community-Engaged Bidirectional Pandemic Crisis and Emergency Risk Communication With COVID-19 Vaccine Messages to Minority Populations

Pancoronavirus Vaccine Study in Healthy Adults

CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2)

COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients

COVID-19 Vaccine Text Outreach

A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19